VIRACTA THERAP.I.DL-0001
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trial… Read more
Market Cap & Net Worth: VIRACTA THERAP.I.DL-0001 (RYI)
VIRACTA THERAP.I.DL-0001 (F:RYI) has a market capitalization of $3.65 Million (€3.56 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #33874 globally and #3858 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VIRACTA THERAP.I.DL-0001's stock price €0.09 by its total outstanding shares 39744200 (39.74 Million).
VIRACTA THERAP.I.DL-0001 Market Cap History: 2015 to 2025
VIRACTA THERAP.I.DL-0001's market capitalization history from 2015 to 2025. Data shows change from $34.72 Million to $3.65 Million (-21.57% CAGR).
VIRACTA THERAP.I.DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VIRACTA THERAP.I.DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RYI by Market Capitalization
Companies near VIRACTA THERAP.I.DL-0001 in the global market cap rankings as of March 19, 2026.
Key companies related to VIRACTA THERAP.I.DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
VIRACTA THERAP.I.DL-0001 Historical Marketcap From 2015 to 2025
Between 2015 and today, VIRACTA THERAP.I.DL-0001's market cap moved from $34.72 Million to $ 3.65 Million, with a yearly change of -21.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €3.65 Million | -39.12% |
| 2024 | €6.00 Million | -71.18% |
| 2023 | €20.81 Million | -56.41% |
| 2022 | €47.73 Million | -60.47% |
| 2021 | €120.76 Million | +97.99% |
| 2020 | €60.99 Million | +367.19% |
| 2019 | €13.05 Million | -3.32% |
| 2018 | €13.50 Million | -88.90% |
| 2017 | €121.61 Million | -11.49% |
| 2016 | €137.40 Million | +295.77% |
| 2015 | €34.72 Million | -- |
End of Day Market Cap According to Different Sources
On Feb 2nd, 2026 the market cap of VIRACTA THERAP.I.DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.65 Million USD |
| MoneyControl | $3.65 Million USD |
| MarketWatch | $3.65 Million USD |
| marketcap.company | $3.65 Million USD |
| Reuters | $3.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.